Evidence map›Paper›PMID 38116246›Full record

ArticleMolecular & cellular oncology2023

APOBEC3 as a driver of genetic intratumor heterogeneity.

Subramanian Venkatesan, Mihaela Angelova, Jirina Bartkova, Samuel F Bakhoum, Jiri Bartek, Nnennaya Kanu, Charles Swanton

Abstract read
In one paragraph

Article in Molecular & cellular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Cancer cells subvert the primate-specific KRAB zinc finger protein ZNF93 to control APOBEC3B.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Subramanian VenkatesanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID https://orcid.org/0000-0001-6454-8508
Mihaela AngelovaCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Jirina BartkovaGenome Integrity Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.
Samuel F BakhoumHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jiri BartekGenome Integrity Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.
Nnennaya KanuCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, UK.
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3M
Probing cytosolic nucleic acid sensing pathways in cancerR01CA256188 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LAUGHNEY, ASHLEY MARIE · 2021 to 2025
$3.5M
The role of chromosomal instability in tumor evolutionDP5OD026395 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI BAKHOUM, SAMUEL F · 2018 to 2022
$2.2M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA256188NIH HHS DP5 OD026395Wellcome Trust FC001169
6 · The paper itself

Abstract

Our recent study revealed that APOBEC3B is upregulated during the preinvasive stages of non-small cell lung cancer and breast cancer. In addition to its role in mediating single nucleotide variants, we propose that APOBEC3 promotes copy number intratumor heterogeneity prior to invasion, providing a substrate for cancer evolution.

Indexed as

APOBECbreast cancerchromosomal instabilityintratumor heterogeneitynon-small cell lung cancer

Identifiers

PMID38116246
PMCPMC10730158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.